18 July 2023
Physiomics plc
("PYC" or the "Company")
Director Dealing
The Company announces that Dr Christophe Chassagnole, Chief Operating Officer of Physiomics, has transferred, for no consideration, 500,000 ordinary shares of 0.4p each in the Company held in certificated form ("Ordinary Shares") to his nominee account with Interactive Investor Services Limited. The Ordinary Shares remain beneficially owned by Dr Chassagnole.
Accordingly, Dr Chassagnole's total holding in the Company will remain unchanged at 1,102,723 Ordinary Shares, representing approximately 0.81 per cent. of the Company's issued share capital.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO +44 (0)1865 784 980
Hybridan LLP (Broker) +44 (0) 203 764 2341
Claire Louise Noyce
Strand Hanson Ltd (NOMAD) +44 (0)20 7409 3494
James Dance
James Bellman
The Company's LEI is 213800A71DSZ6ABMTQ91
PDMR Notification Forms
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Christophe Chassagnole | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | Executive Director, COO | ||||
| b) | Initial notification/amendment | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Physiomics plc | ||||
| b) | LEI | 213800A71DSZ6ABMTQ91 | ||||
| 4. | Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument | Physiomics plc Ordinary Shares | ||||
| Identification code | ISIN: GB00BDR6W943 | |||||
| b) | Nature of the Transaction | Transfer of securities held in paper share certificates to nominee account Interactive Investor Services Nominees Limited. | ||||
| c) | Price(s) and volume(s) | Dr Christophe Chassagnole
| ||||
| d) | Aggregated information - Aggregated volume
- Price
|
500,000 N/A | ||||
| e) | Date of the transaction | 14 July 2023 | ||||
| f) | Place of the transaction | Off market transaction | ||||
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 100 projects, involving over 50 targets and 75 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
